Table 1.
Baseline Characteristics for Patients Receiving Venetoclax-Based Low-Intensity Induction
| No Laboratory TLS (N = 89) |
Laboratory TLS (N = 59) |
|
|---|---|---|
| Age (years) | 72 (56 - 86) | 72 (49 – 86) |
| Male | 50 (56.2) | 31 (52.5) |
| AML Etiology | ||
| Newly Diagnosed | 56 (62.9) | 35 (59.3) |
| Secondary AML with No Prior Treatment | 7 (7.9) | 5 (8.5) |
| Secondary AML with Prior Treatment | 12 (13.5) | 14 (23.7) |
| Therapy-Related AML | 14 (15.7) | 5 (8.5) |
| Myelomonocytic AML | 9 (10.1) | 2 (3.4) |
| Tumor Burden | ||
| Baseline WBC Count (x 109/L) | 3.7 (0.3 – 52.6) | 4.4 (0.4 – 25.5) |
| Baseline LDH Level (U/L) | 479 (108 – 3594) | 689 (167 – 7770) |
| Genetic Mutations | ||
| NPM1 | 14 (15.7) | 13 (22.0) |
| CEBPA | 3 (3.4) | 3 (5.1) |
| FLT3 | 13 (14.6) | 6 (10.2) |
| IDH1 | 9 (10.1) | 5 (8.5) |
| IDH2 | 6 (6.7) | 11 (18.6) |
| TP53 | 28 (31.5) | 15 (25.4) |
| RUNX1 | 13 (14.6) | 13 (22.0) |
| ASXL1 | 19 (21.3) | 12 (20.3) |
| KMT2A | 1 (1.1) | 1 (1.7) |
| GATA2 | 5 (5.6) | 2 (3.4) |
| Baseline Organ Function | ||
| LVEF (%) | 60 (45 – 70) | 59 (30 – 70) |
| Serum Creatinine (mg/dL) | 0.92 (0.42 – 1.80) | 0.90 (0.46 – 3.23) |
| Total Bilirubin (mg/dL) | 0.6 (0.2 – 2.4) | 0.7 (0.2 – 2.5) |
| Induction Regimen | ||
| Decitabine 20 mg/m2 x 5 Days | 21 (23.6) | 15 (25.4) |
| Decitabine 20 mg/m2 x 10 Days | 59 (66.3) | 39 (66.1) |
| Azacitidine 75 mg/m2 x 7 Days | 8 (9.0) | 3 (5.1) |
| Cytarabine 20 mg BID x 10 Days | 0 (0.0) | 1 (1.7) |
| Other* | 1 (1.1) | 1 (1.7) |
| Concomitant Interacting Agents | ||
| Posaconazole | 29 (32.6) | 13 (22.0) |
| Voriconazole | 12 (13.5) | 12 (20.3) |
| Isavuconazole | 15 (16.9) | 13 (22.0) |
| Fluconazole | 1 (1.1) | 1 (1.7) |
Data presented as mean (range) or N (%), as appropriate
TLS = tumor lysis syndrome; AML = acute myeloid leukemia; WBC = white blood cell
LDH = lactate dehydrogenase; LVEF = left ventricular ejection fraction; BID = twice daily
*
Includes Decitabine 10 mg/m2 x 5 Days (no TLS) and Decitabine 20 mg/m2 x 7 Days (laboratory TLS)